Tissue Repair & Regenerative
Overview
Peptides studied for tissue repair, angiogenesis and extracellular-matrix remodeling — BPC-157, TB-500 (Thymosin β4), their synergy and a comparison page.
| Compound | Class | Mechanism | Primary research targets |
|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | NO modulation, VEGF/FGF, gastroprotection | Tendon, ligament, GI, neural repair |
| TB-500 (Ac-SDKP) | Thymosin β4 fragment | Actin sequestration, VEGF upregulation | Wound, cardiac and muscle repair |
How Tissue Repair Peptides Work
These peptides modulate the tissue-repair cascade through complementary routes. BPC-157 is studied for nitric-oxide-system modulation, angiogenic growth-factor upregulation and fibroblast activation; TB-500 — the Ac-SDKP fragment of Thymosin β4 — is an actin-sequestering peptide that drives endothelial and epithelial cell migration and angiogenesis. Studied alone or in combination, they cover angiogenesis, cell migration, inflammation resolution and extracellular-matrix remodeling.
1. Angiogenesis
Both upregulate VEGF/FGF; TB-500 drives endothelial-cell migration through actin binding.
2. Cell migration & proliferation
BPC-157 stimulates fibroblasts and keratinocytes; TB-500 promotes endothelial and epithelial migration.
3. Extracellular-matrix remodeling
BPC-157 upregulates collagen I/III synthesis; TB-500 modulates matrix-metalloproteinase activity.
4. Anti-inflammatory signalling
Downregulate TNF-α, IL-6 and IL-1β; upregulate IL-10 and TGF-β.
5. Anti-apoptotic effects
Activate PI3K/Akt and ERK1/2 survival signalling in stressed tissue.
Key Properties at a Glance
| Compound | CAS number | MW (Da) | Length | Mechanism | Half-life |
|---|---|---|---|---|---|
| BPC-157 | 137525-51-2 | 1419.52 | 15 aa | NO modulation, VEGF/FGF, gastroprotection | ~ 15 min |
| TB-500 (Ac-SDKP) | 77591-33-4 | 500.52 | 4 aa | Actin sequestration, VEGF upregulation | ~ 2–6 h |
Research Evidence Summary
Representative reported findings from the literature (qualitative). See each compound page for detail.
| Compound | Key reported finding | Reference |
|---|---|---|
| BPC-157 | Faster tendon functional recovery vs controls | Sikiric P et al. |
| BPC-157 | Protection against NSAID-induced gastric lesions | Sikiric P et al. |
| BPC-157 | Accelerated wound closure and angiogenesis | Seiwerth S et al. |
| TB-500 | Accelerated wound closure and angiogenesis | Malinda KM et al., 1999 |
| TB-500 | Improved post-injury cardiac function | Bock-Marquette I et al., 2004 |
| TB-500 | Enhanced corneal epithelial healing | Sosne G et al., 2005 |
Research Dosing Overview
Typical research dose ranges from the literature (for research reference only, not human dosing guidance):
| Compound | Research dose | Route | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | 10–50 µg/kg | SC / oral | 1–2×/day | 2–8 wk |
| TB-500 (Ac-SDKP) | 1–5 mg | SC / IM | 1–2×/wk | 4–8 wk |
Formulation & Reconstitution
| Factor | Recommendation |
|---|---|
| Solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution | 1–2 mL per vial (peptide-dependent) |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
| Storage (reconstituted) | 2–8°C for up to 7–14 days |
| pH stability range | 5.0–7.0 |
| Oxidation-sensitive residues | Protect Met / Cys peptides from air and light; add antioxidant where relevant |
Selected References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC-157 (review and preclinical literature).
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
- Bock-Marquette I, et al. Thymosin beta-4 promotes cardiac cell survival and repair. Nature, 2004.
- Sosne G, et al. Thymosin beta-4 promotes corneal wound healing. Experimental Eye Research, 2005.
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
